NCT06235918View on ClinicalTrials.gov

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2026

Conditions
Head and Neck Squamous Cell CarcinomasResectable Head and Neck Squamous-cell Carcinoma
Interventions
DRUG

Tislelizumab

Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles

DRUG

Nab-paclitaxel

260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles

DRUG

Carboplatin

AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles

Trial Locations (1)

Unknown

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors
lead

Xiang Lu

OTHER